Search clinical trials for: natalizumab SC

Total 642 results

Biogen

Completed

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS) (REFINE)

Relapsing-Remitting Multiple Sclerosis

France, Italy, Spain, Germany, Belgium
Biogen
Elan Pharmaceuticals; United BioSource, LLC

Completed

JC-Virus (JCV) Antibody Program (STRATIFY-1)

Multiple Sclerosis

United States
Biogen
Elan Pharmaceuticals

Withdrawn

Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy

Crohn's Disease
Biogen
Elan Pharmaceuticals

Completed

Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease

Crohn's Disease
Biogen
Elan Pharmaceuticals

Completed

Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease

Crohn's Disease

United States
Biogen

Completed

Tysabri Observational Program (TOP)

Relapsing-Remitting Multiple Sclerosis

Belgium, Germany, Italy, Norway, France, Mexico, Australia, Spain, Portugal, Greece, Netherlands, United Kingdom, Czechia, Slovakia, Finland, Canada, Argentina, Brazil
Biogen

Completed

Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke (ACTION2)

Acute Ischemic Stroke

Spain, United States, Germany, United Kingdom
Biogen

Completed

Clinical Disease Activity With Long Term Natalizumab Treatment

Relapsing-Remitting Multiple Sclerosis

Czechia, Belgium
Biogen

Terminated

Study of Natalizumab in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
Biogen
Elan Pharmaceuticals

Completed

Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease

Crohn's Disease

United States
Biogen
Elan Pharmaceuticals

Completed

Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease

Crohn's Disease

United States, United Kingdom
University at Buffalo

Completed

Natalizumab Temporary Discontinuation Study (NaTDS)

Multiple Sclerosis

United States
University Hospital, Caen
Biogen

Completed

Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort (RELEVANT)

Multiple Sclerosis, Relapsing-Remitting

France
Biogen

Completed

Ireland Natalizumab (TYSABRI) Observational Program (iTOP)

Relapsing-Remitting Multiple Sclerosis

Ireland
Biogen

Terminated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis (ASCEND in SPMS)

Secondary Progressive Multiple Sclerosis

United States, Finland, Italy, Spain, Canada, France, Israel, Sweden, Netherlands, Belgium, Poland, United Kingdom, Czechia, Denmark, Russian Federation, Germany, Ireland
Biogen
Elan Pharmaceuticals

Completed

Natalizumab Re-Initiation of Dosing

Multiple Sclerosis, Relapsing-Remitting

United States, Canada
Biogen

Completed

A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function (TRUST)

Relapsing-Remitting Multiple Sclerosis
University of South Florida

Completed

The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis (Tysex)

Multiple Sclerosis

United States
Biogen
Elan Pharmaceuticals

Completed

A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients (TIMER)

Relapsing Remitting Multiple Sclerosis (RRMS)

Belgium, Mexico, Poland, Romania, Saudi Arabia, Ukraine
Biogen

Completed

JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab (STRATIFY-2)

Relapsing Multiple Sclerosis

United States, Puerto Rico
Biogen

Completed

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants (STRIVE)

Relapsing-Remitting Multiple Sclerosis

United States
Biogen

Completed

Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With Natalizumab (PROTYS)

Multiple Sclerosis

Switzerland
Biogen

Terminated

Natalizumab Subcutaneous Immunogenicity and Safety Study (SIMPLIFY)

Relapsing Multiple Sclerosis

Belgium
Biogen

Completed

Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri

Multiple Sclerosis
Biogen

Terminated

CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring (INFORM)

Crohn's Disease

United States, Puerto Rico
Cornerstone Health Care, PA
Biogen

Completed

NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness

Multiple Sclerosis, Relapsing-Remitting

United States
Biogen

Terminated

Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies (ESCALATE)

Relapsing Multiple Sclerosis

United States
Biogen

Completed

Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke (ACTION)

Acute Ischemic Stroke

Spain, United States, Germany
Biogen
Elan Pharmaceuticals

Completed

A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease

Crohn's Disease

United States, Canada
Biogen

Completed

Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis

Japan
Biogen

Completed

A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)

Relapsing Forms of Multiple Sclerosis

United States
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Safety and Efficacy of IBI306 in Chinese Subjects With Non-familial Hypercholesterolemia

Hypercholesterolemia

China
University of California, San Diego
University of Oklahoma; University of Southern California; Children's Bureau... and other collaborators

Completed

Evaluating Trauma-Informed, Evidence-Informed Interventions for Latino Families Experiencing Domestic Violence

Interpersonal Relations

United States
Nantes University Hospital
Rennes University Hospital

Active, not recruiting

Comparing the Safety and Benefit of Natalizumab (Tysabri®) At-home Infusion vs At-hospital Infusion in Multiple Sclerosis (Tys at Home)

Multiple Sclerosis (MS)

France
Biogen
Elan Pharmaceuticals

Terminated

A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201

Rheumatoid Arthritis
Biogen

Completed

Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) (Tysabri Japan)

Multiple Sclerosis

Japan
argenx

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia (ADVANCE SC)

Primary Immune Thrombocytopenia

United States, France, Georgia, Germany, Italy, Japan, Poland, Russian Federation, Spain, Turkey, United Kingdom, Argentina, Australia, Bulgaria, Chile, China, Denmark, Greece, Ireland, Israel, Jordan, Korea, Republic of, Mexico, New... and more
StemCells, Inc.

Terminated

Study of Human Central Nervous System (CNS) Stem Cell Transplantation in Cervical Spinal Cord Injury

Cervical Spinal Cord Injury | Spine Injury | Cervical Spine Injury

United States, Canada
Vanderbilt University Medical Center
Biogen

Terminated

Natalizumab and Chronic Inflammation

Multiple Sclerosis

United States
Biogen
Elan Pharmaceuticals

Completed

Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)

Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

United States
argenx

Recruiting

A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease. (UplighTED)

Thyroid Eye Disease

United States
Biogen
Elan Pharmaceuticals

Completed

Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease

Crohn's Disease

United States
Biogen
Elan Pharmaceuticals

Completed

Natalizumab High Titer Immunogenicity and Safety

Multiple Sclerosis

United States
Hangzhou Sumgen Biotech Co., Ltd.

Recruiting

SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus (SLE)

China
Eli Lilly and Company

Completed

A Study of LY3461767 in Healthy Participants

Healthy

United States, Singapore
Berkovich, Regina MD, PhD Inc.
Biogen; Cedars-Sinai Medical Center

Recruiting

A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

United States
Federal University of Health Science of Porto Alegre
Irmandade Santa Casa de Misericórdia de Porto Alegre

Unknown

Pelvic Physiotherapy in the Prevention of Vaginal Stenosis Secondary to the Radiotherapy (PPPVSSR)

Gynecologic Cancer | Pathological Constriction

Brazil
University of Florida
Genentech, Inc.

Not yet recruiting

Satralizumab in Aneurysmal Subarachnoid Hemorrhage (SASH)

Delayed Cerebral Ischemia | Aneurysmal Subarachnoid Hemorrhage

United States
Amsterdam UMC, location VUmc
Innovatiefonds Zorgverzekeraars; Stichting MS Research; Stichting Treatmeds

Enrolling by invitation

Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis (SUPERNEXT)

Relapsing Remitting Multiple Sclerosis

Netherlands
Eli Lilly and Company

Terminated

A Study of LY3478006 in Healthy Participants

Healthy

United States

Search clinical trials for: natalizumab SC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovakia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations